Drug Database
EC
eculizumab (Ablyze)
✓ ApprovedCinnagen Co · C5 · Monoclonal Antibodies
What is eculizumab?
eculizumab is a monoclonal antibodies developed by Cinnagen Co. It is approved for therapeutic indications via injectable (others) or intravenous (iv).
Drug Profile
| Brand Names | Ablyze |
| Company | Cinnagen Co |
| Drug Class | Monoclonal Antibodies, Antibody |
| Molecular Target | C5 |
| Route | Injectable (Others), Intravenous (IV) |
| Status | Approved |
Sources: ClinicalTrials.gov, Cinnagen Co
Mechanism of Action
Molecular Targets
eculizumab acts on 1 molecular target:
| C5 | complement C5 (C5b, C5D) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Therapeutic Indications
eculizumab is developed for 4 unique indications across 3 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Blood and lymphatic system disorders | Haemolytic uraemic syndrome | ✓ Approved |
| Nervous system disorders | Myasthenia gravis | ✓ Approved |
| Renal and urinary disorders | Paroxysmal nocturnal haemoglobinuria | ✓ Approved |
| Nervous system disorders | Neuromyelitis optica spectrum disorder | ✓ Approved |
Related Research Articles
Unable to load articles right now.